MARLBOROUGH, Mass.,
Nov. 7, 2017 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi
company developing innovative therapeutics that address significant
unmet medical needs, announced today that its leadership team will
be participating in several leading European healthcare forums and
conferences.
November 13, 2017 – World
HealthEx Forum
On November 13,
2017, Dr. Karen Bulock, Vice
President of Research at RXi Pharmaceuticals, will participate in
the Immuno-Oncology HealthEx World Forum, one of eight dynamic
sessions taking place at World HealthEx Forum. Industry
leaders will gather to discuss and address key challenges for
businesses fighting the most devastating human diseases of our
time.
This forum provides a platform for executives from pharma,
health technology, finance, and government dedicated to finding
solutions to the health industry's most pressing challenges through
debate, dialogue, and collaboration. This conference will take
place November 13, 2017, at 200
Aldersgate, London, UK.
November 14, 2017 – Biotech and
Money Inv€$tival Showcase
Dr. Bulock will present during the
2017 Inv€$tival Showcase on November 14,
2017, at 1:45 pm GMT where she
will discuss the Company's proprietary self-delivering RNAi
(sd-rxRNA®) platform and demonstrate its broad applicability for
cell-based immunotherapies to treat cancer.
In an exclusive partnership with Jefferies LLC, the Inv€$tival
Showcase spans 4-tracks and will feature the most exciting
companies across seven key sub-sectors within life sciences. The
global list of presenting companies will span corporates involved
in the World HealthEx Forum on November
13, as well as the most exciting and innovative new
companies looking to raise capital or profile with investors,
brought together through both Biotech and Money and Jefferies'
investor networks. This conference will take place November 14, 2017, at Waldorf Hilton Hotel
London, UK.
November 13-14, 2017 – CEO
Forum in Europe
Dr.
Geert Cauwenbergh, President and CEO
at RXi Pharmaceuticals, will present during a panel on November
14, 2017 to discuss "Raising
Capital for your Business" at the CEO Forum in Europe sponsored by YJP.
This Forum provides for learning and networking opportunities
with top-level business executives from both sides of the Atlantic
Ocean. The intimate format, organized in part with Bayer, allows
for deeper and more meaningful interactions with like-minded
executives to explore important topics related to leadership and
innovation. This conference will take place November 13-14, 2017 at Bayer Pharmaceuticals,
Berlin, Germany.
November 15-16, 2017 –
Jefferies Healthcare Conference
Dr. Cauwenbergh will be
participating in the largest 2-day European healthcare conference
where he will focus on business development and partnering
opportunities.
Now in its eighth year, the Jefferies Conference is the largest
healthcare-dedicated conference in Europe. This year, we hosted 350 participating
companies, 1,400 attendees and 3,400 investor and
business-to-business meetings. The event featured leading public
and private companies from the pharmaceuticals, biotechnology,
generics, consumer health, animal health, medical technology and
healthcare services sectors from the
United States, Europe,
Africa, Middle East, Latin
America, Russia,
India, Israel, China, and Japan. The conference will
take place November 15-16 in
London, UK.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage company developing innovative therapeutics that
address significant unmet medical needs. Building on the
pioneering discovery of RNAi, scientists at RXi have harnessed the
naturally occurring RNAi process which can be used to "silence" or
down-regulate the expression of a specific gene that may be
overexpressed in a disease condition. RXi developed a robust
RNAi therapeutic platform, including self-delivering RNA
(sd-rxRNA®) compounds, that have the ability to highly selectively
block the expression of any target in the genome, thus providing
applicability to many therapeutic areas. Our current programs
include dermatology, ophthalmology, and cell-based
immunotherapy. RXi's extensive patent portfolio provides for
multiple product and business development opportunities across a
broad spectrum of therapeutic areas, and we actively pursue
research collaborations, partnering and out-licensing opportunities
with academia and pharmaceutical companies. For additional
information, visit the Company's website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
Logo-
http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg
View original
content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-announces-participation-in-leading-european-healthcare-forums-and-conferences-300550611.html
SOURCE RXi Pharmaceuticals Corporation